Brenna E. Swift
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brenna E. Swift has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Lilian T. Gien
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1E2, Canada
4 shared publications Allan Covens
University of Toronto, Department of Obstetrics & Gynecology, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Odette Cancer Centre, Department of Obstetrics and Gynaecology, Division of Gynecologic Oncology, Toronto, ON, Canada
3 shared publications- Genevieve Bouchard-Fortier
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1E2, Canada
3 shared publications - Anna Kobylianskii
Department of Obstetrics and Gynaecology, University of Toronto, Temerty Faculty of Medicine, Toronto, ON, Canada
2 shared publications - Anouk Benseler
Department of Obstetrics and Gynecology University of Toronto Toronto Ontario Canada
2 shared publications Azusa Maeda
Division of Gynecologic Oncology, Princess Margaret Cancer Centre/University Health Network/Sinai Health System, Toronto, Ontario, Canada
2 shared publications
Latest Publications
- 30 July 2026
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 48  (10)
Video-Based Surgical Coaching in Gynaecologic Surgery
- 30 July 2026
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 48  (10)
Video-Based Surgical Coaching in Gynaecologic Surgery
- Open Access
- 18 May 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36  (7) , 104766
Feasibility and recurrence risk of sentinel lymph node biopsy in large vulvar tumors (≥4 cm)
- 18 May 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36  (7) , 104766
Open AccessFeasibility and recurrence risk of sentinel lymph node biopsy in large vulvar tumors (≥4 cm)
- 11 March 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36  (5) , 104640
Patterns of care of gestational trophoblastic disease in Ontario: a population-based study
- 11 March 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36  (5) , 104640
Patterns of care of gestational trophoblastic disease in Ontario: a population-based study
- Open Access
- 11 February 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36  (4) , 104555
Association of body mass index and length of stay in patients undergoing minimally invasive surgery for uterine cancer: a National Surgical Quality Improvement Program (NSQIP) study
- 11 February 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36  (4) , 104555
Open AccessAssociation of body mass index and length of stay in patients undergoing minimally invasive surgery for uterine cancer: a National Surgical Quality Improvement Program (NSQIP) study
- Open Access
- 23 April 2025
- Published by BMJ in BMJ Medicine
- Vol. 4  (1) , e001017
Monitoring complete hydatidiform molar pregnancies after normalisation of human chorionic gonadotrophin: national retrospective population study
Objective: To provide evidence for a reduced surveillance protocol to detect gestational trophoblastic neoplasia after normalisation of human chorionic gonadotrophin (hCG) levels following uterine evacuation of a complete hydatidiform mole. Design: National retrospective population study Setting: Two UK Trophoblastic Disease Treatment Centres (Sheffield and London), 1 January 1980 to 30 November 2020. Participants: 17 424 patients with hCG normalisation after evacuation of their complete hydatidiform mole were included. Complete hydatidiform moles were verified by centralised pathological review. Patients were excluded if lost to follow-up or required treatment before normalisation of hCG levels. Main outcome measures: Incidence and clinical presentation of gestational trophoblastic neoplasia after normalisation of hCG levels following uterine evacuation of a complete hydatidiform mole. Results: Of 17 424 patients whose hCG normalised after complete hydatidiform mole evacuation, 99.8% (n=17 393 of 17 424) did not subsequently develop gestational trophoblastic neoplasia. The overall risk of gestational trophoblastic neoplasia after previous normalisation of hCG levels was 0.2% (n=31 of 17 424 patients). The risk of developing gestational trophoblastic neoplasia after uterine evacuation was substantially lower if hCG levels returned to normal in v 0.22%, 0.15% to 0.31%), with a posterior relative risk of 0.25 (0.06 to 0.72). Most patients who developed gestational trophoblastic neoplasia (71.0%, n=22 of 31) had received a diagnosis after the current six month surveillance protocol. The cumulative risk of developing gestational trophoblastic neoplasia in patients whose hCG levels normalised early increased minimally with time. If a patient had normal hCG levels in <56 days, a clinically relevant time point, the risk of developing gestational trophoblastic neoplasia was small (0.04%, about 1 in 2619 patients) at 39 months after normalisation. The equivalent risk for a patient who had normal hCG levels in ≥56 days was 0.16% (about 1 in 642 patients). All 31 women who developed gestational trophoblastic neoplasia achieved sustained remission after subsequent treatment. Conclusions: The findings of the study indicate that surveillance protocols could safely change to one confirmatory normal hCG value for patients whose hCG levels return to normal in <56 days of evacuation of a complete hydatidiform mole. Patients whose hCG levels return to normal in ≥56 days should be counselled on the remaining risk of gestational trophoblastic neoplasia over time to help decide the length of subsequent follow-up.
- 23 April 2025
- Published by BMJ in BMJ Medicine
- Vol. 4  (1) , e001017
Open AccessMonitoring complete hydatidiform molar pregnancies after normalisation of human chorionic gonadotrophin: national retrospective population study
Objective: To provide evidence for a reduced surveillance protocol to detect gestational trophoblastic neoplasia after normalisation of human chorionic gonadotrophin (hCG) levels following uterine evacuation of a complete hydatidiform mole. Design: National retrospective population study Setting: Two UK Trophoblastic Disease Treatment Centres (Sheffield and London), 1 January 1980 to 30 November 2020. Participants: 17 424 patients with hCG normalisation after evacuation of their complete hydatidiform mole were included. Complete hydatidiform moles were verified by centralised pathological review. Patients were excluded if lost to follow-up or required treatment before normalisation of hCG levels. Main outcome measures: Incidence and clinical presentation of gestational trophoblastic neoplasia after normalisation of hCG levels following uterine evacuation of a complete hydatidiform mole. Results: Of 17 424 patients whose hCG normalised after complete hydatidiform mole evacuation, 99.8% (n=17 393 of 17 424) did not subsequently develop gestational trophoblastic neoplasia. The overall risk of gestational trophoblastic neoplasia after previous normalisation of hCG levels was 0.2% (n=31 of 17 424 patients). The risk of developing gestational trophoblastic neoplasia after uterine evacuation was substantially lower if hCG levels returned to normal in v 0.22%, 0.15% to 0.31%), with a posterior relative risk of 0.25 (0.06 to 0.72). Most patients who developed gestational trophoblastic neoplasia (71.0%, n=22 of 31) had received a diagnosis after the current six month surveillance protocol. The cumulative risk of developing gestational trophoblastic neoplasia in patients whose hCG levels normalised early increased minimally with time. If a patient had normal hCG levels in <56 days, a clinically relevant time point, the risk of developing gestational trophoblastic neoplasia was small (0.04%, about 1 in 2619 patients) at 39 months after normalisation. The equivalent risk for a patient who had normal hCG levels in ≥56 days was 0.16% (about 1 in 642 patients). All 31 women who developed gestational trophoblastic neoplasia achieved sustained remission after subsequent treatment. Conclusions: The findings of the study indicate that surveillance protocols could safely change to one confirmatory normal hCG value for patients whose hCG levels return to normal in <56 days of evacuation of a complete hydatidiform mole. Patients whose hCG levels return to normal in ≥56 days should be counselled on the remaining risk of gestational trophoblastic neoplasia over time to help decide the length of subsequent follow-up.
- Open Access
- 26 March 2025
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 32  (8) , 701-708.e1
A Multicenter, Randomized Controlled Trial to Assess Video-Based Surgical Coaching in Gynecology
- 26 March 2025
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 32  (8) , 701-708.e1
Open AccessA Multicenter, Randomized Controlled Trial to Assess Video-Based Surgical Coaching in Gynecology
- Open Access
- 30 November 2024
- Published by Elsevier in Journal of Surgical Education
- Vol. 82  (1) , 103351
Mindfulness in Surgical Training (MiST): A Modified Mindfulness Curriculum for Surgical Residents
- 30 November 2024
- Published by Elsevier in Journal of Surgical Education
- Vol. 82  (1) , 103351
Open AccessMindfulness in Surgical Training (MiST): A Modified Mindfulness Curriculum for Surgical Residents
- 14 December 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34  (4) , 602-609
Predictors and outcomes of same day discharge after minimally invasive hysterectomy in gynecologic oncology within the National Surgical Quality Improvement Program database
Objective To assess trends over time of same day discharge after minimally invasive hysterectomy in oncology, identify perioperative factors influencing same day discharge, and evaluate 30 day postoperative morbidity. Methods A retrospective cohort of elective minimally invasive hysterectomies performed for gynecologic oncologic indications between January 2013 and December 2021 was identified using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. Clinical and surgical characteristics, length of stay, and 30 day postoperative complications were captured. Clinical and surgical factors affecting same day discharge rate and impact of same day discharge on postoperative outcomes were evaluated using χ2 tests and logistic regression. Results Patients undergoing minimally invasive hysterectomy (n=32 823) had a same day discharge rate of 34.5% over the 9 year period, increasing from 15.5% in 2013 to 55.1% in 2021. The rate of patients discharged on postoperative day 1 decreased from 76.4% to 41.4% over this period. On multivariable analysis, same day discharge decreased with: age 70–79 years (odds ratio (OR) 0.80) and ≥80 years (OR 0.42); body mass index 40–49.9 kg/m2 (OR 0.89) and ≥50 kg/m2 (OR 0.67); patient comorbidities, including hypertension (OR 0.85), chronic steroid use (OR 0.74), bleeding disorder (OR 0.54), anemia (OR 0.89), and hypoalbuminemia (OR 0.76); and surgical time >90th percentile (OR 0.40) (all p2 (OR 1.28, 95% CI 1.08 to 1.51) and ≥50 kg/m2 (OR 1.60, 95% CI 1.27 to 2.01) were associated with greater 30 day composite morbidity. Conclusion In this study, same day discharge following minimally invasive hysterectomy for oncologic indications was safe, and rates are rising among all age and body mass index categories. Quality improvement initiatives are needed at oncology centers to promote early discharge after minimally invasive gynecologic oncology surgery.
- 14 December 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34  (4) , 602-609
Predictors and outcomes of same day discharge after minimally invasive hysterectomy in gynecologic oncology within the National Surgical Quality Improvement Program database
Objective To assess trends over time of same day discharge after minimally invasive hysterectomy in oncology, identify perioperative factors influencing same day discharge, and evaluate 30 day postoperative morbidity. Methods A retrospective cohort of elective minimally invasive hysterectomies performed for gynecologic oncologic indications between January 2013 and December 2021 was identified using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. Clinical and surgical characteristics, length of stay, and 30 day postoperative complications were captured. Clinical and surgical factors affecting same day discharge rate and impact of same day discharge on postoperative outcomes were evaluated using χ2 tests and logistic regression. Results Patients undergoing minimally invasive hysterectomy (n=32 823) had a same day discharge rate of 34.5% over the 9 year period, increasing from 15.5% in 2013 to 55.1% in 2021. The rate of patients discharged on postoperative day 1 decreased from 76.4% to 41.4% over this period. On multivariable analysis, same day discharge decreased with: age 70–79 years (odds ratio (OR) 0.80) and ≥80 years (OR 0.42); body mass index 40–49.9 kg/m2 (OR 0.89) and ≥50 kg/m2 (OR 0.67); patient comorbidities, including hypertension (OR 0.85), chronic steroid use (OR 0.74), bleeding disorder (OR 0.54), anemia (OR 0.89), and hypoalbuminemia (OR 0.76); and surgical time >90th percentile (OR 0.40) (all p2 (OR 1.28, 95% CI 1.08 to 1.51) and ≥50 kg/m2 (OR 1.60, 95% CI 1.27 to 2.01) were associated with greater 30 day composite morbidity. Conclusion In this study, same day discharge following minimally invasive hysterectomy for oncologic indications was safe, and rates are rising among all age and body mass index categories. Quality improvement initiatives are needed at oncology centers to promote early discharge after minimally invasive gynecologic oncology surgery.
- 22 September 2023
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 46  (1) , 102226
Access to Surgery for Endometrial Cancer Patients During the COVID-19 Pandemic in Ontario, Canada: A Population-Based Study
- 22 September 2023
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 46  (1) , 102226
Access to Surgery for Endometrial Cancer Patients During the COVID-19 Pandemic in Ontario, Canada: A Population-Based Study
- Open Access
- 15 February 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33  (4) , 585-591
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery
Objective To examine the incidence of perioperative blood transfusion and association with 30 day postoperative outcomes in gynecologic cancer surgery. Methods The American College of Surgeons National Surgical Quality Improvement Program database was queried to identify all gynecologic oncology cases from 2013 to 2019. Clinical and surgical characteristics and 30 day postoperative complications were retrieved. The primary outcome was 30 day composite morbidity, based on the occurrence of one or more of the 18 adverse events. Secondary outcomes were 30 day mortality, length of stay in hospital, and composite surgical site infection, defined as superficial, deep, or organ space surgical site infection. The χ2 test and logistic regression analyses were performed to compare the outcomes of patients with and without perioperative blood transfusion. Results There were 62 531 surgical gynecologic oncology cases with an overall transfusion incidence of 9.4%. The transfusion incidence was significantly higher at 22.4% with laparotomy compared with 1.7% with minimally invasive surgery (pConclusion Perioperative blood transfusion is associated with increased composite morbidity and prolonged length of stay in hospital. Preoperative patient optimization and institutional practices should be reviewed to improve the use of blood bank resources and adherence to restrictive blood transfusion protocols.
- 15 February 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33  (4) , 585-591
Open AccessAdverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery
Objective To examine the incidence of perioperative blood transfusion and association with 30 day postoperative outcomes in gynecologic cancer surgery. Methods The American College of Surgeons National Surgical Quality Improvement Program database was queried to identify all gynecologic oncology cases from 2013 to 2019. Clinical and surgical characteristics and 30 day postoperative complications were retrieved. The primary outcome was 30 day composite morbidity, based on the occurrence of one or more of the 18 adverse events. Secondary outcomes were 30 day mortality, length of stay in hospital, and composite surgical site infection, defined as superficial, deep, or organ space surgical site infection. The χ2 test and logistic regression analyses were performed to compare the outcomes of patients with and without perioperative blood transfusion. Results There were 62 531 surgical gynecologic oncology cases with an overall transfusion incidence of 9.4%. The transfusion incidence was significantly higher at 22.4% with laparotomy compared with 1.7% with minimally invasive surgery (pConclusion Perioperative blood transfusion is associated with increased composite morbidity and prolonged length of stay in hospital. Preoperative patient optimization and institutional practices should be reviewed to improve the use of blood bank resources and adherence to restrictive blood transfusion protocols.